2012, Number 2
<< Back Next >>
Patol Rev Latinoam 2012; 50 (2)
Her-2/neu expression in gastric adenocarcinoma, 10 years experience (2001-2011) in the Unidad Médica de Alta Especialidad No. 25, Centro Médico Nacional Noreste
Esquivel HO, Castelan MEE, Espinoza BMP
Language: Spanish
References: 21
Page: 80-86
PDF size: 372.53 Kb.
ABSTRACT
Gastric cancer is the most common malignancy of the digestive tract worldwide. Adenocarcinoma accounts for 90% -95% of all malignancies of the stomach. There have been studies on the expression of Her-2/neu in cancer of the stomach. Several studies showed that overall survival and time of occurrence of relapses in patients with these neoplasms was lower in those who had higher levels of this oncogene, suggesting that Her-2/neu could be used as a prognostic factor. Increased expression of Her-2/neu and its accessibility make this receptor a suitable target for direct anti-tumor therapy.
Objectives: To assess the expression of Her2/neu in gastric adenocarcinomas.
Material and methods: observational, analytical and retrospective study in which we observe the expression of Her-2/neu, were studied in 65 total gastrectomy with a diagnosis of adenocarcinoma, were selected paraffin blocks, to which they were performed with hematoxylin staining and eosin and immunohistochemistry.
Results: The immunohistochemical reaction produced by the Her2/neu antibody was positive in only six cases (9.23%), and negative in 59 cases (90.76%). Four (66.66%) were found in body and antrum. It was observed that the expression of Her2/neu is related to the degree of infiltration in four cases (66.66%) was observed in the serous infiltration, and in the remaining two (33.33%) a muscle.
Conclusion: We found a low prevalence (9.23%) of the expression of Her2/neu, the figures are within international standards.
REFERENCES
Tierney L, McPhee SJ, Papadakis MA y col. Tumores malignos del estómago. Diagnóstico clínico y tratamiento. 35ª ed. p. 585-586.
Corral VB. Cáncer gástrico, estado actual. Cirujano General. 1999; 21.
Serrano A, Hernández MC, De la Garza Salazar J, Herrera L. Helicobacter pylori y Cáncer Gástrico. Revista INCAN 2009;193-204.
Zinner MJ, Scwartz SI, Ellis H. Tumores gástricos. Operaciones abdominales 10ª ed. p. 927-954.
Morales R, Méndez MJ, Aranda E. Cáncer de estómago. Medicine 2005;9(25):1613-1620.
Pisters PW, Kelsen DP, Powell SM, Tepper JE. Cancer of stomach. DeVita V, Hellman S, Rosenberg S. (edts.) Principles and Practice of Oncology. 7ª th ed. Philadelphia: Lippincot William and Wilkins; 2005. p.909-944.
Gunderson LL, Donohue JH, Alberts SR. Cáncer gástrico. En: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (edts.) Oncología clínica. 3ª ed. Madrid: Editorial Elsevier; 2005;1819-1863.
Michelin SC, Mayo J. El oncogén c-erbB-2 (neu/Her-2) y su expresión en el cáncer de mama humano. Revista Latinoamericana de Mastología, 1997;2(3):181-190.
Liang Z, Zeng X, Jie G, y col. El análisis de EGFR, HER2, y el estado de Top2A genes y polisomía cromosómica en el adenocarcinoma gástrico de los pacientes chinos. BMC cáncer 2008;8:363.
Weinstat-Saslow D, Merino MJ, Manrow RE. et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Medicine 1995;1(12):1257-1260.
Polkowski W, Van Sandick JW, Offerhaus GA, et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Annals of Surgical Oncology, 1999;6(3):290–297.
Flejou JF, Paraf F, Muzeau F, et al. Expression of c-erbB-2 oncogene product in Barrett’s adenocarcinoma: pathological and prognostic correlations. Journal of Clinical Pathology 1994;47(1):23–26.
Nakamura T, Nekarda H, Hoelscher AH, et al., Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer 1994;73(7):1785–1794.
Brien TP, Odze RD, Sheehan CE, McKenna BJ, and Ross JS, Her-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Human Pathology 2000;31(1):35–39.
Hung MC, Martin A, Zhang Y, et al. HER-2/neu-targeting gene therapy- a review. Gene 1995;159:65-71.
Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Research 1997;57:1199-1205.
Tanner M, Hollmén M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of Oncology 2005;16(2):273–278.
Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. Journal of the National Cancer Institute 2009;101(19):1306–1307.
Gravalos C and Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology 2008;19(9):1523–1529.
Wu CW, Chen GD, Fann CS et al. Clinical implications of chromosomal abnormalities in gastric adenocarcinomas. Genes Chromosomes and Cancer 2002;35(3):219–231.
Cirne FK, De Souza A, Kulczynski JM, Mattana DS, Corezolla K, Moreira LF. Immunohistochemical expression of HER-2/ NEU-CERBB-2 in patients with adenocarcinoma of the stomach. Rev Col Bras Cir 2009;36(2):131-134.
Full text